DNA viruses promote cell cycle progression, stimulate unscheduled DNA synthesis, and present the cell with an extraordinary amount of exogenous DNA. These insults elicit vigorous responses mediated by cellular factors that govern cellular homeostasis. To ensure productive infection, adenovirus has developed means to inactivate these intracellular antiviral responses. Among the challenges to the host cell is the viral DNA genome, which is viewed as DNA damage and elicits a cellular response to inhibit replication. Adenovirus therefore encodes proteins that dismantle the cellular DNA damage machinery. Studying virus-host interactions has yielded insights into the molecular functioning of fundamental cellular mechanisms. In addition, it has suggested ways that viral cytotoxicity can be exploited to offer a selective means of restricted growth in tumor cells as a therapy against cancer. In this review, we discuss aspects of the intracellular response that are unique to adenovirus infection and how adenoviral proteins produced from the early region E4 act to neutralize antiviral defenses, with a particular focus on DNA damage signaling.
Introduction
Virus infections challenge the host with foreign material in the form of proteins and nucleic acids. These assaults upon the host cell inevitably induce antiviral responses. In the dynamic warfare that is established, there will be battles won by either side as the virus attempts to control the cell, and the cell in turn tries to keep the invader at bay. The adenoviruses have provided a powerful model for studying virus-host interactions and tools to unravel molecular mechanisms in mammalian cells (reviewed in Ben-Israel and Kleinberger, 2002; Burgert et al., 2002; Russell et al., 2004; O'Shea, 2005) . Detailed knowledge of their genetic composition has also facilitated their development into vectors for gene delivery and exploitation for tumor cell killing. The molecular constitution of tumor cells differs from that of normal cells, and this may impact the balance between virus infection and host defenses. These differences between normal cells and tumor cells are exploited by oncolytic viral agents, which are designed to replicate selectively for cancer therapy. Understanding how intracellular antiviral defenses, such as the DNA damage response, affect viral growth will direct improvements to these viral weapons.
The cell mounts a multifaceted response to adenovirus infection in an attempt to inhibit viral gene expression, disrupt viral DNA replication and promote death of the infected cell. Additional arms of the response serve to signal other cells of the viral encounter and to facilitate recognition of the infected cell by the immune system. This multifaceted response of the cell is met by an equally diverse array of viral activities involving multiple transcription regions that aim to counter these host responses. Many of the viral proteins that combat the host immune responses have been described in detail by a number of excellent recent reviews (see Horwitz, 2001; Burgert et al., 2002; Fessler et al., 2004; Lichtenstein et al., 2004; Schaack, 2005) . In this review, we have therefore chosen to focus on aspects of the disarming of the intracellular response that involve the early region 4 (E4) of the adenoviral genome. Recent studies suggest that the ability of the adenoviral E4 proteins to promote viral gene expression through interactions with cellular targets is key to overcoming some of the intracellular barriers encountered during adenovirus infection. Here we review the current state of knowledge of E4 functions and their potential implications for tumor therapy. We will specifically deal with how these proteins counter the DNA damage response, cell cycle restrictions and obstacles to growth through regulation of protein translation.
Introduction to the adenovirus genome and its replication
The adenovirus genome
The adenovirus genome consists of a linear doublestranded DNA molecule of approximately 36 kb (Shenk, 1996) . At either end are inverted terminal repeats (ITRs), which contain sequences that serve as the origins for DNA replication. The genes are grouped into transcriptional units: five early (E1a, E1b, E2, E3 and E4), two delayed early and one major late unit.
Each region is transcribed to yield multiple mRNAs through the use of alternative splicing and differential polyadenylation. In many cases, the transcription units generate products that carry out related functions within the temporally regulated viral life cycle. There are also two viral-associated (VA) RNAs transcribed from a polymerase III promoter. Early proteins not only promote expression of key viral and cellular genes, but also suppress the ability of the cell to mount an antiviral response.
Adenovirus gene expression and replication
The E1a gene encodes proteins that play a major role in the transcriptional regulation of viral and cellular genes (Shenk and Flint, 1991; Nevins, 1995; Frisch and Mymryk, 2002 ; discussed in detail by Berk in this issue). E1a is the first gene to be transcribed and is alternatively spliced to generate viral proteins that fulfill a plethora of functions, including transcriptional activation and induction of the host cell into S phase. In addition to promoting early viral gene expression, the E1a proteins inhibit activation of genes induced by interferon (IFN) and IL-6 (Anderson and Fennie, 1987; Reich et al., 1988; Takeda et al., 1994) , and may thus blunt the effect of inflammatory cytokines and chemokines. The E1b region produces two gene products involved in countering cellular responses. The E1b19K protein is a functional homolog of the cellular protein BCL2 that inhibits apoptosis and prevents the premature death of the infected cells that would limit virus production (Cuconati and White, 2002) . The E1b55K protein forms a complex with the adenoviral E4orf6 protein that promotes degradation of cellular proteins, disarms the cellular DNA damage response and facilitates the preferential nucleo-cytoplasmic transport of late adenoviral mRNA (Dobner and Kzhyshkowska, 2001; Flint and Gonzalez, 2003) .
Proteins encoded by the adenovirus E2 genes are essential for viral DNA replication (de Jong et al., 2003; Liu et al., 2003) . Adenoviral DNA replication is initiated by a protein priming mechanism involving the preterminal protein (pTP), which is covalently attached to the 5 0 end of the genomic DNA. Viral DNA is synthesized by the E2b DNA polymerase. The E2a gene encodes a single-stranded DNA-binding protein (DBP) that is required for viral DNA replication and also regulates transcription and translation of viral genes during the late stages of infection (Shenk, 1996) .
Many viral proteins counter the host immune response to adenovirus infection (Horwitz, 2001) . The E3 region encodes proteins specifically involved in immune evasion (Fessler et al., 2004; Lichtenstein et al., 2004) . The E3 proteins affect the functioning of cell surface receptors, intracellular signaling events and secretion of proinflammatory molecules. There is also an E3 product that promotes cell death to facilitate release of progeny virions late in the infection cycle (Tollefson et al., 1996) . Together, these E3 proteins protect infected cells from inflammatory challenges and cytolysis.
Transcription of the E4 region is regulated by a single promoter that is activated early in infection by E1a and there are six known E4 proteins that are produced temporally through alternative splicing (Dix and Leppard, 1993; Leppard, 1997; Tauber and Dobner, 2001b) . Transcription declines at later times in infection due to repression by E2a, and by feedback inhibition of E1a-mediated E4 transactivation by the E4orf4 protein (Bondesson et al., 1996) . A mutant virus lacking the E4 region is severely impaired, with defects in viral DNA replication, accumulation of late viral messages and proteins, virus particle assembly and shut-off of host protein synthesis (Halbert et al., 1985; Weinberg and Ketner, 1986; Yoder and Berget, 1986; Falgout and Ketner, 1987; Sandler and Ketner, 1989) .
The E4 region and its functions
Genetic analysis of the E4 region (mainly in tumor cells) showed that mutations within individual open reading frames have minimal or modest effects (Halbert et al., 1985; Bridge and Ketner, 1989; Huang and Hearing, 1989) . This is partly due to functional redundancy between E4orf3 and E4orf6, while the other E4 gene products are dispensable for lytic growth of the virus, at least in tumor cells analysed in vitro. Expression of an E4orf1 protein has only been detected for some of the serotypes and mutations in Ad5 E4orf1 have minimal effects on viral growth in most cells. However, deletion of E4orf1 was deleterious to virus growth in primary cells (Frese et al., 2003; O'Shea et al., 2005) . The E4orf4 product is not essential for virus growth and its deletion has minimal effect in tumor cells (Halbert et al., 1985; Branton and Roopchand, 2001 ). However, a mutant expressing E4orf4 in the absence of all other E4 genes was highly defective for DNA synthesis, suggesting an inhibitory role for the viral protein in regulating replication (Bridge et al., 1993) . The E4orf4 product affects protein phosphorylation during infection through binding to protein phosphatase 2A (PP2A), one of the major serine/threonine-specific phosphatases in the cell (Kleinberger and Shenk, 1993) . E4orf4 also inhibits colony formation by inducing apoptosis of transformed cells in a p53-independent manner Marcellus et al., 1998; Shtrichman and Kleinberger, 1998) that also requires interaction with PP2A (Shtrichman et al., 1999; Marcellus et al., 2000) .
The E4orf3 protein is highly conserved, associates with the nuclear matrix and induces the reorganization of nuclear bodies called PML oncogenic domains (PODs) or ND10 (Doucas et al., 1996) . These are large nuclear structures that contain proteins implicated in multiple cellular functions including transformation, genomic stability, DNA repair, transcriptional control, apoptosis and the IFN response (Borden, 2002) . E4orf3 expression induces rearrangement of PODs into tracklike structures, when it is ectopically expressed and in the context of viral infection (Carvalho et al., 1995; Doucas et al., 1996) . The mechanism by which E4orf3 accomplishes these drastic changes in the architecture of nuclear structures and the cellular consequence of POD disruption are not clear. As many viruses target the PODs and in some cases rearrange their components, it has been suggested that reorganization is advantageous for viral replication (Maul, 1998; Everett, 2001) . E4orf3 may play a role in the initiation of viral replication (Evans and Hearing, 2003) , although its functions are dispensable at high multiplicities of infection (Doucas et al., 1996) . E4orf3 has been shown to bind E1b55K, relocalizing it to the nucleus and recruiting it into the discrete PML tracks (Konig et al., 1999) . E4orf3 may be situated to counter the multifaceted antiviral response through its ability to target constituents of the PODs and because of its ability to regulate late viral gene expression.
The E4orf6 gene encodes a 34 kDa protein that is highly conserved across a variety of adenovirus serotypes (Boyer and Ketner, 2000) . E4orf6 has a central cysteine-rich section, which forms a functional zincbinding domain (Boyer and Ketner, 2000) . There is also a conserved arginine-rich region at the C-terminus of E4orf6 that forms an amphipathic a-helix important for its function (Orlando and Ornelles, 1999; Cathomen and Weitzman, 2000) . E4orf6 forms a complex with the viral E1b55K protein that is involved in viral DNA replication, RNA processing, nucleo-cytoplasmic transport of late viral mRNA and the shut-off of host protein synthesis. E4orf6 also recruits cellular factors including Cullin-5, Elongin B and Elongin C into a ubiquitin ligase that together with E1b55K mediates polyubiquitinylation and degradation of cellular targets (Querido et al., 2001; Harada et al., 2002) . The targeting of cellular proteins for proteasome-mediated degradation may be one of the ways that the E1b55K/E4orf6 complex functions to inactivate cellular antiviral defenses. This complex also facilitates export of late viral mRNAs at the expense of cellular RNAs (Dobner and Kzhyshkowska, 2001; Flint and Gonzalez, 2003) . The complex can shuttle between the nucleus and the cytoplasm, and nuclear export signals of differing strength have been reported for both E1b55K (Kratzer et al., 2000) and E4orf6 (Dobbelstein et al., 1997) .
Adenovirus and the cellular DNA damage machinery
Adenovirus may be unique among animal viruses because its genome exists predominantly as discrete monomers of double-stranded DNA throughout the course of a productive infection. At late times of infection, amplification of the linear adenovirus genome presents the cell with as many as 100 000 doublestranded DNA ends. The host cell responds to this new insult by activation of the cellular DNA damage response (Stracker et al., 2002; Carson et al., 2003) , which can be construed as an antiviral response. The viral genome elicits a DNA damage response but this is only detected in the absence of a functional E4 region. The DNA repair machinery therefore functions as an obstacle to adenovirus infection but the wild-type virus has developed E4-encoded strategies to inactivate this intracellular antiviral response.
The DNA damage response to adenovirus infection
Mammalian cells have evolved an elaborate network of cellular checkpoints that monitor the integrity of genomic DNA during cell proliferation. DNA damage results in activation of signal transduction pathways that control cell cycle progression, the DNA repair machinery and programmed cell death (Zhou and Elledge, 2000; Bartek and Lukas, 2001; Rouse and Jackson, 2002) . A central player in the cellular response to DNA double-strand breaks (DSBs) is the Mre11 complex, containing Mre11, Rad50 and NBS1 proteins (D'Amours and Jackson, 2002; Stracker et al., 2004) . Protein phosphorylation is the principal method of signaling used by the damage response, and two central signal transducers are the related PI3-like protein kinases, ataxia-telangiectasia mutated (ATM) and ATM-Rad3-related (ATR). It has been proposed that ATM is activated by intermolecular autophosphorylation on Ser1981 and dimer dissociation, which enables phosphorylation of substrate proteins (Bakkenist and Kastan, 2003; Bakkenist and Kastan, 2004) . ATR may be recruited to sites of DNA damage by its cofactor ATRIP and by RPA bound to single-stranded DNA (Zou and Elledge, 2003) . Many cellular DNA repair and checkpoint proteins are substrates for ATM and ATR kinase activity (Kastan and Lim, 2000; Shiloh, 2003) . These include the downstream checkpoint kinases Chk1 and Chk2, and other damage response proteins such as 53BP1, H2AX, BRCA1, p53 and RPA32. Both Mre11 and NBS1 proteins are also targets of ATM and possibly ATR (D'Amours and Jackson, 2002; Lavin, 2004) . This same apparatus that recognizes damage to the host genomic DNA also appears to respond to adenovirus infection. In the absence of the E4 region, the cellular machinery is activated, ultimately resulting in joining together of viral genomes in a DNA repair pathway.
Early after adenovirus infection with a virus that lacks the E4 genes, the signaling pathways characteristic of a cellular response to DNA DSBs are activated (Stracker et al., 2002; Carson et al., 2003) . This can be detected using phospho-specific antibodies that recognize modified residues on DNA repair proteins. The ATM kinase becomes activated, as demonstrated by autophosphorylation on S1981, and many of the known substrates for ATM and ATR become phosphorylated. Infections in mutant cell lines showed that there is some redundancy for ATM, ATR and possibly other kinases in signaling (Carson et al., 2003) . The signaling events require the Mre11 complex (Carson et al., 2003) and are not observed during infection with wild-type virus due to inactivation of the complex by the E4 proteins (see below).
Proteins involved in the cellular response to DNA damage are recruited to sites of DSB in the host genome and appear as foci within the nucleus of damaged cells. Many of these proteins are found to form foci surrounding viral replication centers during infection with the E4-deleted adenovirus, including the Mre11 complex and the autophosphorylated form of ATM (Stracker et al., 2002; Carson et al., 2003) . The Mre11 complex accumulates in foci at the virus centers even in the absence of ATM and ATR signaling. This suggests that recognition of the virus is an upstream event that occurs prior to kinase activation. It is not yet known what viral structures are specifically recognized by the cellular repair machinery. Viral replication presents the cell with a large amount of foreign DNA, which will contain unusual DNA structures and replication intermediates. The adenovirus genome also possesses a terminal protein that is covalently linked to the 5 0 end of the genome to initiate replication. This protein-DNA complex may represent a substrate for recognition and processing by the Mre11 complex, analogous to the situation with Spo11, which requires the Mre11 complex for its removal from DSBs during meiotic recombination.
The result of the cellular DNA damage response to adenovirus infection is processing of the viral genome into concatemers. Infection with viruses deleted of E4 results in the formation of large concatemers of viral DNA that can be detected by pulsed field gel electrophoresis. These concatemers consist of covalently linked molecules with no specific orientation and heterogeneous junctions (Weiden and Ginsberg, 1994 ). There appears to be a requirement for the nonhomologous end-joining repair pathway, as concatemers are not produced in cells with mutant DNA-PKcs (Boyer et al., 1999; Stracker et al., 2002) and ligase IV (Stracker et al., 2002) . In addition, concatemerization requires the Mre11 complex and is not observed in mutant cell lines (Stracker et al., 2002) . Although neither ATM nor ATR is absolutely required for concatemer formation, there may be a role for signaling pathways in the processing and joining of viral genomes (MD Weitzman, unpublished observations).
Inactivating the damage response
In contrast to the E4-deleted adenovirus, during infection with wild-type virus, the genome is observed as a linear monomer and there is no activation of ATM and ATR signaling (Stracker et al., 2002; Carson et al., 2003) . This suggests that the E4 region encodes viral factors that can prevent both viral concatemer formation and activation of the cellular DNA damage response. Adenovirus has evolved two mechanisms to dismantle the obstacle of DNA repair during infection, thus preventing activation of cellular checkpoints and concatemerization. There is redundancy between E4orf3 and E4orf6 proteins for their ability to prevent concatemer formation and both achieve this by targeting the Mre11 complex (Stracker et al., 2002) . Early after infection, the Mre11/Rad50/NBS1 proteins are redistributed from their diffuse localization in the nucleoplasm into nuclear speckles and cytoplasmic aggregates. The E4orf3 protein is sufficient to reorganize the Mre11 complex components, which partially colocalize in nuclear tracks with E4orf3 (Stracker et al., 2002 Evans and Hearing, 2005) . In addition to mislocalization, infection is also accompanied by proteasome-mediated degradation of the Mre11 complex proteins. The E1b55K/E4orf6 proteins of adenovirus are responsible for targeting degradation of the Mre11 complex (Stracker et al., 2002) , and E1b55K binds to the complex (Carson et al., 2003) . This suggests that members of the Mre11 complex may also be substrates for modification by the ubiquitin ligase that is recruited by E4orf6.
The E4orf3 and E4orf6 proteins can each rescue an E4-deleted virus by preventing concatemerization, and both affect signaling in the cellular DNA damage response. Expression of the E4orf3 protein from Ad5 can prevent accumulation of the Mre11 complex at viral replication centers , and can also abrogate ATR-mediated phosphorylation events during infection (MD Weitzman, unpublished observations). Inhibition of concatemer formation and ATR activation correlates with redistribution of the Mre11 complex MD Weitzman, unpublished observations) . E4orf3 also induces the accumulation of the Mre11 complex components into cytoplasmic aggregates that assemble into a structure that resembles an aggresome , and this could contribute to its inactivation. Mislocalization of the Mre11 protein can be separated from POD disruption (Evans and Hearing, 2005; Stracker et al., 2005) and in the absence of E4orf6, it may also play a role in promoting virus replication (Evans and Hearing, 2005) . Degradation of the Mre11 complex by the adenovirus E1b55K/E4orf6 proteins blocks joining of viral genomes and also prevents the cell from mounting a DNA damage response to DSBs (Stracker et al., 2002; Carson et al., 2003) . Degradation of the Mre11 complex correlates with prevention of ATM activation and checkpoint induction, consistent with an upstream sensor role for the complex (Carson et al., 2003) .
The E4orf6 protein may also have some effects that are independent of its association with E1b55K and the Mre11 complex. For example, expression of E4orf6 can radiosensitize cells (Hart et al., 2005) . Although E4orf6 does not inhibit the kinase activity of DNA-PKcs on an in vitro substrate (Boyer et al., 1999; Hart et al., 2005) , it can prolong the autophosphorylation of DNA-PKcs (Hart et al., 2005) , implying an inhibition of dephosphorylation.
The cellular tumor suppressor protein p53 is also part of the cellular response to DNA damage, and is itself a phosphorylation target of the kinases activated by DNA damage (Wahl and Carr, 2001) . Infections with mutant viruses that do not express either E1b55K or E4orf6 gene products results in stabilization of p53 protein levels (Grand et al., 1994; Steegenga et al., 1998) , which may reflect phosphorylation and effects mediated by the viral E1a polypeptides (Lowe and Ruley, 1993) . Even higher levels of p53 protein accumulated in cells infected with a double-mutant virus deleted of both E1b55K and E4orf3 genes (DA Ornelles, unpublished observations). The E1b55K/E4orf6 complex promotes proteasomal degradation of p53 during viral infections (Grand et al., 1994; Querido et al., 1997; Steegenga et al., 1998; Cathomen and Weitzman, 2000) . The E4orf6 and E1b55K proteins can also both independently inhibit the transcriptional activity of p53 through direct binding (Yew and Berk, 1992; Dobner et al., 1996; Cathomen and Weitzman, 2000) . Therefore, functions of p53 in the cellular responses to DNA damage are inactivated during infection with wild-type adenovirus.
The cell cycle restriction to adenovirus infection
In addition to their role in countering the DNA damage response to virus infection, the E4orf3, E4orf6 and E1b55K proteins have also been implicated in overcoming cell cycle restrictions to virus replication. It is possible that these disparate activities are actually connected to each other. Infections with virus mutant in E1b55K and E4orf6 revealed that virus replication can be affected by the stage of the cell cycle at the time of infection. When individual cells infected with these viruses were evaluated by electron microscopy or by assays for infectious centers, approximately one in five cells contained progeny virus Ornelles, 1997, 1999; Shepard and Ornelles, 2003) . Infections in synchronized cells showed that cells infected during S phase produced more progeny mutant virus than cells infected during G1 Ornelles, 1997, 1999) . By contrast, all cells infected with the wild-type virus produced progeny virus irrespective of the cell cycle. Therefore, the cell cycle can be considered an obstacle to productive adenovirus infection that is manifested as a G1 restriction.
The G1 restriction is overcome by the ability of the E1b55K/E4orf6 complex to promote late viral gene expression. Analysis of the growth of mutant viruses bearing in-frame insertions in the E1b55K gene demonstrated that only those viruses that failed to express late viral genes efficiently were restricted by G1 (Goodrum and Ornelles, 1999). The ability of the E1b55K protein to inactivate p53 had no impact on the cell cycle restriction (Goodrum and Ornelles, 1997 Ornelles, , 1998 . Rather, the molecular basis for the cell cycle restriction appears to be linked to decreased efficiency of late viral mRNA export in G1 cells. The ratio of cytoplasmic to nuclear viral mRNA was decreased in G1 cells infected with either the E1b55K or E4orf6 mutant virus compared to the wild-type virus (Goodrum and Ornelles, 1999; Gonzalez and Flint, 2002) . By contrast, the efficiency of late viral mRNA transport in S-phase-infected cells was identical among cells infected with mutant or wildtype viruses (Goodrum and Ornelles, 1999) . The G1 restriction may also be exerted at the level of translation (Goodrum and Ornelles, 1999; DA Ornelles, unpublished observations). It is possible that the regulation of translation in S-phase cells, like that in tumor cells, differs substantially from the regulation of translation in G1 or nontumor cells (see the review by Mohr in this issue). The E4orf3 protein is also important for overcoming cell cycle restrictions. Adenoviruses deleted of the E4orf3 and either E1b55K or E4orf6 genes are severely defective for late gene expression. In contrast to the E1b55K or E4orf6 single-mutant viruses, the double-mutant viruses did not derive any benefit from infecting S-phase cells (Goodrum and Ornelles, 1999; Shepard and Ornelles, 2003) . The need for E4orf3 to enhance replication in S-phase-infected cells was unexpected because deletion of E4orf3 alone has no effect on virus yield or viral gene expression (Halbert et al., 1985; Huang and Hearing, 1989) . Thus, although E4orf3 cannot overcome the G1 restriction, E4orf3 is important for enhanced S-phase replication of E1b55K and E4orf6 mutant viruses.
The cellular activity that imposes the G1 restriction remains unknown. RNA transport may generally be less efficient in G1-infected cells compared to S-phaseinfected cells. If so, late viral mRNA transport may require E1b55K/E4orf6 function in G1 cells, whereas late viral mRNA transport in S-phase cells may require only E4orf3 function. Another possibility is that the E1b55K/E4orf6 complex is needed to suppress a cellular response that is elicited in G1-infected cells. If this cellular response is different or less robust in S-phaseinfected cells, the response may be suppressed by E4orf3 alone. A candidate for such a response that is linked to the cell cycle is the DNA damage response. Because Sphase cells experience transient single-and doublestranded DNA breaks during cellular DNA synthesis, the DNA damage response during S phase is different from that during G1. Indeed, it has been shown that cells are least sensitive to the DNA-damaging effects of ionizing radiation at late parts of S phase (Sinclair and Morton, 1966) . Adenovirus infection releases linear double-stranded molecules of DNA into the nucleus and consequently infection immediately presents the cell with molecules that can trigger the DNA damage response. Therefore, if the DNA damage response is elicited early after infection, this response could be considered to be an antiviral response that is more robustly expressed in the G1-infected cell than in the S-phase-infected cell. It may therefore be significant that the E1b55K/E4orf6 protein complex and the E4orf3 protein share the ability both to promote late viral gene expression and to block the DNA damage response.
Regulation of protein translation during adenovirus infection
All viruses require the cellular translation apparatus for the synthesis of viral polypeptides. Therefore, a common antiviral strategy is to disable the translation process. One mechanism by which this occurs is through phosphorylation of Ser51 of the alpha subunit of the eucaryotic initiation factor (eIF-2a). Protein kinases activated in response to signals associated with virus infection and the early events of virus replication phosphorylate eIF-2a, which leads to inactivation of a limiting factor required for initiation of translation, eIF-2B. As a result, the rate of translational initiation on typical messenger RNA is reduced. Since the production of progeny virus requires adequate synthesis of viral proteins, viruses have evolved means to block inactivation of translation (Schneider and Mohr, 2003) . Adenovirus both prevents the phosphorylation of eIF2a and overcomes antiviral responses that might otherwise inhibit translation in the early stages of infection (This is also discussed by Shmulevitz and Lee and by Barber and Mohr in their reviews in this issue.)
The control of translation at early times of infection
The type I IFNs induce synthesis of the double-stranded RNA-activated protein kinase (PKR). PKR is one of four enzymes that phosphorylate eIF-2a, and is one of many IFN-inducible antiviral effectors regulated by the IFN-regulatory family (IRF) of transcription factors. These transcription factors are important for expression of the IFN genes as well as for expression of several hundred IFN-activated genes (Samuel, 2001) . IRF members such as IRF-3 and IRF-7 are latent transcription factors that are phosphorylated by a virus-activated kinase and become incorporated into a cellular complex termed DRAF1. Like PKR, DRAF1 is activated by double-stranded RNA (Weaver et al., 1998) . Additional transcription factors important to the IFN response include the signal transduction and activator of transcription (STAT) and nuclear factorkappaB (NF-kB). These transcription factors and the DRAF1 complex require chromatin-remodeling proteins such as p300/CBP for activity. It is this requirement that enables the adenovirus E1a proteins to counter the antiviral effects of IFN at multiple steps.
The E1a proteins directly and indirectly block transcription of both IFN genes and IFN-responsive genes. The E1a proteins directly bind STAT and NF-kB and interfere with their ability to stimulate transcription (Leonard and Sen, 1996; Look et al., 1998) . The aminoterminal domain of the E1a proteins binds transcriptional coactivators such as CBP/p300, p400, GCN5, P/CAF and TRAPP (Frisch and Mymryk, 2002; Lang and Hearing, 2003) . While bound to E1a, the transcriptional coactivators are no longer available for transcription factors such as NF-kB or for the DRAF1 complex. Through these interactions, the E1a proteins can suppress transcription of a wide variety of antiviral effectors.
Double-stranded RNA permits dimerization of PKR, which leads to autophosphorylation and activation (Kaempfer, 2003) . Double-stranded RNA is believed to arise in the adenovirus-infected cell from transcripts synthesized from opposing promoters at early times of infection, although evidence for significant amounts of this double-stranded RNA is lacking. Adenovirus encodes two small (160 nucleotide) virus-associated RNAs transcribed by RNA polymerase III that antagonize activation of PKR by double-stranded RNA (Burgert et al., 2002) . Mutational analysis of the abundant VAI RNA suggests that this highly structured RNA contains a double-stranded RNA domain that can only bind a single PKR molecule, thereby competitively preventing activation of PKR (Ghadge et al., 1994) . Early studies established that VAI RNA mutant viruses induced high levels of phosphorylated eIF2a, suffered reduced viral and host cell translation, and were defective for replication in some, although not all cells (Kitajewski et al., 1986) . Subsequent studies have suggested that cells with activated Ras pathways contain an inhibitor of PKR (Mundschau and Faller, 1994) and are not restrictive for the VAI RNA mutant viruses (Cascallo et al., 2003) . These tumor cells are defective in their ability to mount the early antiviral response to adenovirus that is mediated by PKR.
Translation in the late adenovirus-infected cell
After the onset of viral DNA replication, the battle over the control of translation is reversed. At early times of infection, the host cell is poised to shut off translation by the action of the IFN-inducible enzymes such as PKR. The PKR-mediated shut off of translation is prevented at the transcriptional level by E1a and at the posttranscriptional level by VAI RNA. However, at late times of infection, adenovirus itself blocks translation. This reversal in the battle over translation prevents antiviral responses that depend on new gene expression. Protection from intracellular pathogens and the suppression of aberrant cell growth share the need to recognize and eliminate wayward cells. This common goal is evident by the convergence of type I IFN signaling and p53-mediated pathways Pestka, 2003; Takaoka et al., 2003; MunozFontela et al., 2005) . New transcripts that are produced in response to signaling through these pathways must be translated in order to have an impact. Many viruses therefore prevent antiviral responses by blocking new host gene expression at several steps (Lyles, 2000) . Elements of the cellular DNA damage response to the virus may also be inactivated through regulation of host protein translation by adenovirus. At late times of infection, products of the E4 region act directly and indirectly to block new host gene expression. In association with the E1b55K protein, E4orf6 directly prevents nuclear export of cellular mRNA (Dobner and Kzhyshkowska, 2001; Tauber and Dobner, 2001b; Flint and Gonzalez, 2003) . By promoting late viral gene expression, the E4orf6/E1b55K and E4orf3 proteins indirectly block host gene expression by increasing expression of the nonstructural adenoviral 100K protein of L4. The 100K protein serves the dual function of blocking host translation while promoting late viral protein translation.
The L4 100K protein blocks host translation and promotes viral translation
The L4 100K protein product blocks translation by altering the composition and phosphorylation state of the eIF4F protein complex. This multiprotein complex binds to the 5 0 terminal cap structure of typical eucaryotic mRNA to initiate translation (Kapp and Lorsch, 2004; Richter and Sonenberg, 2005) . eIF4F includes three initiation factors: eIF4A (an ATPdependent helicase important for unwinding terminal secondary structures), eIF4E (the cap-binding protein) and a large scaffold protein eIF4G. Phosphorylated eIF4E is associated with active translation, whereas conditions of diminished eIF4E phosphorylation are associated with reduced translation. At late times of adenovirus infection, eIF4E is underphosphorylated (Huang and Schneider, 1991) . Work of Schneider and associates established that the 100K protein displaces Mnk1 from eIF4F, thus preventing phosphorylation of eIF4E (Cuesta et al., 2001) . In this way, adenovirus compromises the ability of the eIF4F cap-binding complex to initiate translation on most mRNA. Adenovirus late mRNAs escape this block by using the modified eIF4F cap-binding complex to initiate translation by the unusual mechanism of ribosome shunting (Xi et al., 2004) . Ribosome shunting allows adenovirus late mRNAs to escape the block to translation even though they are capped and polyadenylated in an identical manner to cellular mRNA (Schneider and Mohr, 2003) . The 100K protein also recruits translation factors to the 5 0 end of late viral mRNA and promotes functional circularization of the mRNA independently of the phosphorylation status of the cap-binding protein eIF4E (Cuesta et al., 2000) . The 100K protein accomplishes this as part of the modified eIF4F complex through its ability to bind specifically to late viral mRNA and the poly(A)-binding protein. The 100K protein contains both nonspecific (Adam and Dreyfuss, 1987; Riley and Flint, 1993) and sequence-specific RNAbinding domains (Xi et al., 2004 (Xi et al., , 2005 . As part of eIF4F, the 100K protein binds the tripartite leader in a tyrosine phosphorylation-specific manner (Xi et al., 2004 (Xi et al., , 2005 . Therefore, through interactions with viral mRNA, eIF4G and the poly(A)-binding protein, the 100K protein recruits factors required for translation of viral mRNA in the face of the overall inhibition to cap-dependent translation.
Implications for tumor therapy
The lessons derived from studies of the natural biology of adenovirus infections will also have implications for the potential harnessing of adenovirus and its proteins for cancer therapy. The interactions of adenovirus products with key cellular regulators, together with knowledge of the molecular differences between normal and tumor cells can be exploited to target death of cancer cells.
Replicating oncolytic adenoviruses
Adenovirus replication ultimately results in death of the infected cell. Although the myriad of paths that lead to cell death are complex, harnessing this cell killing in a tumor-selective fashion is the goal of oncolytic therapies (Bischoff et al., 1996; Kirn, 2000; Dobbelstein, 2004) . The oncolytic nature of many viruses including adenovirus reflects an intrinsic property of the cancer cell (Bell et al., 2002) . Cancer cells are believed to arise from the dysregulation of multiple pathways that regulate cell growth and survival (Hanahan and Weinberg, 2000) . These changes include proliferation in the absence of extracellular signals, diminished apoptosis, resistance to growth-suppressive cytokines including IFN and increased rates of protein synthesis. The machinery that recognizes DNA damage and activates cellular checkpoints is also inactivated in cancer cells. Adenovirus expresses genes that achieve these same changes in the course of a productive infection. For example, the E1a (Frisch and Mymryk, 2002) and E4 proteins (Tauber and Dobner, 2001a) promote cellular proliferation, the E4 proteins potentiate growth signals transmitted through the PI3-kinase pathway (Frese et al., 2003; O'Shea et al., 2005) , the E1b proteins block apoptosis (Cuconati and White, 2002) and the E4 proteins dismantle the cellular DNA damage response (Stracker et al., 2002; Carson et al., 2003) . In addition, the E3 proteins as well as interactions among E1a, E1b and E2 proteins blunt the response to proinflammatory and death-inducing signals (McNees and Gooding, 2002; Fessler et al., 2004; Schaack, 2005) . Consequently, intrinsic properties of cancer cells may obviate the need for specific viral functions that act to reprogram the cell to favor virus replication. These features have been exploited by a number of strategies aimed at creating oncolytic viruses with increased selectivity for cancer cells. This is discussed in detail by O'Shea in this issue.
An important characteristic of a replicating, oncolytic virus is the ability to replicate and cause death more efficiently in tumor cells compared to normal cells. Viruses such as ONYX-015 are attractive oncolyic agents (Bischoff et al., 1996) that replicate better in tumor cells compared to normal cells, reflecting unique properties of tumor cells including cell cycle differences. Additionally, both E4orf6 and E1b55K mutant viruses killed S-phase-infected cells more rapidly than G1-infected cells (Goodrum and Ornelles, 1998; Shepard and Ornelles, 2003; DA Ornelles, unpublished observations) . Since a number of reports showed that the E1b55K mutant viruses replicated within and killed a variety of tumor cells irrespective of p53 status (Goodrum and Ornelles, 1998; Harada and Berk, 1999; Steegenga et al., 1999; Dix et al., 2001) , it has been suggested that the oncolytic nature of the E1b55K mutant virus may be more closely linked to the cell cycle-restricted nature of the virus rather than the p53 status of the cell. Recently, O'Shea et al. (2004) concluded that late viral RNA transport is more efficient in tumor cells than in normal cells. This may suggest that the efficiency of mRNA transport and translation varies in different stages of the cell cycle.
The E4 proteins may also be a contributing factor to the observed synergy between oncolytic adenovirus and either chemotherapy or radiation Li et al., 2001; Dilley et al., 2005) . The precise reason for this synergy is unknown, but inactivation of cellular DNA damage responses by E4 proteins sensitizes tumor cells to the other treatments. Therefore, retaining the E4 region may be beneficial for these vectors in some settings.
E4 gene products as antitumor agents
The identification of DNA repair proteins as targets for the E4 gene products has raised the idea of their potential use as a novel means to radiosensitize tumor cells. Cells with mutations in Mre11 and NBS1 are hypersensitive to DNA-damaging agents and patients are predisposed to tumor development (Stewart et al., 1999; Kobayashi et al., 2004; . In addition, cells deficient in DNA-PKcs activity are hypersensitive to radiation and other DNA-damaging agents (Burma and Chen, 2004; Meek et al., 2004; Collis et al., 2005) . Therefore, inactivation of either the Mre11 complex or DNA-PKcs by the E4 proteins could radiosensitize tumor cells. Expression of E4orf6 alone has recently been shown to induce radiosensitization of human glioblastoma and colorectal carcinoma cells (Hart et al., 2005) . The precise mechanism for the sensitization is not clear but it occurred in the absence of other viral proteins. It could be due to an inhibitory effect on Mre11, DNA-PKcs or another repair factor. Sustained autophosphorylation of DNA-PKcs that was observed in the presence of E4orf6 (Hart et al., 2005) may signal that repair has been incomplete and this would trigger growth arrest or cell death. These results suggest that E4orf6 could be used as an adjuvant gene therapy approach for solid tumors.
The E4orf4 gene product has also been proposed as a potential tool in cancer gene therapy (Branton and Roopchand, 2001 ). E4orf4 expression is highly toxic and it can induce a novel form of p53-independent apoptosis in cancer cells but not in normal human cells Shtrichman and Kleinberger, 1998; Shtrichman et al., 1999; Marcellus et al., 2000; Kleinberger, 2004) . The exact mechanism for cell killing in mammalian cells is not known, but is thought to require binding to PP2A. E4orf4 has also been linked to dysregulation of Src family kinases, which could lead to rearrangement of the actin cytoskeleton and loss of survival signals (Lavoie et al., 2000) . E4orf4 becomes phosphorylated by Src kinase, which regulates its subcellular localization and aspects of the death signal (Gingras et al., 2002) . The E4orf4 protein might therefore be exploited as a tumorspecific killing agent, and study of its mechanism of action might also identify cellular targets to aid in the development of novel small molecule anticancer drugs.
Conclusions
The recent studies linking adenovirus infection to the cellular DNA damage machinery demonstrate that viruses can be useful model systems for studying aspects of DNA repair. In the case of adenovirus, the targeting of the Mre11 complex by E4 and E1b proteins demonstrated that the cellular complex can play a role as a sensor of viruses and DNA damage in general (Stracker et al., 2002; Carson et al., 2003) . The antiviral responses activated during adenovirus infection are likely to be similar to those encountered by other viruses. The cellular DNA repair machinery probably recognizes the DNA genomes of many viruses, but what may serve as a barrier for adenovirus may be exploited to aid the growth of other viruses. For example, recent studies have demonstrated the accumulation of cellular DNA repair factors at the replications centers formed by herpes simplex virus (HSV) infection (Taylor and Knipe, 2004; Wilkinson and Weller, 2004; Lilley et al., 2005) . HSV does not appear to inactivate completely the damage machinery and may even exploit repair proteins to aid its own replication (Taylor and Knipe, 2004; Lilley et al., 2005) . In this case, the Mre11 complex is also involved in the cellular response (Lilley et al., 2005) . The cellular DNA repair apparatus is probably also harnessed during integration into the host genome during infection by retroviruses and parvoviruses Skalka and Katz, 2005) . The terminal repeats of parvoviruses are also recognized by repair proteins and this may result in activation of a damage response or recombination between viral ends (Raj et al., 2001; Zentilin et al., 2001; Duan et al., 2003) . Therefore, what may appear as antiviral responses to one virus may be manipulated in beneficial ways by other viruses.
Since the synthesis of viral proteins depends completely on cellular translational machinery, a predominant innate defense against viral invaders is the wholesale suppression of translation. Therefore, many viruses including adenovirus have evolved mechanisms to take control of protein translation within the infected cell. Elaborate strategies have been adopted to ensure the translation of viral mRNAs while preventing the translation of cellular mRNA in order to diffuse antiviral responses (Thompson and Sarnow, 2000; Schneider and Mohr, 2003) . Inactivation of PKR and the eIF4F translation initiation complex in conjunction with ribosome shunting as an alternative means of initiating translation are strategies used by adenovirus that are common to other viruses (Schneider and Mohr, 2003) .
Viral-induced cell death can be the by-product of a successful lytic infection. The nature of the cell death reflects the balance between the host antiviral responses and the methods employed by the virus to inactivate them. Most studies of the adenovirus life cycle have been performed with infections of transformed cells grown in tissue culture. These cannot accurately reflect all aspects of the regulation of the infectious pathway and the interactions with host responses. The kinetics of transcription, gene expression and replication may be very different during the natural in vivo setting of infection, and genes identified as nonessential for the virus may prove otherwise in the natural setting.
In spite of its inherent limitations, the study of adenovirus-host interactions in vitro has provided tremendous insight into the inner workings of the mammalian cell. Cellular proteins that act as key regulators of fundamental cellular processes are often the targets of virus countermeasures. Just as viruses have been useful tools in studies of replication, transcription and cell cycle control, their manipulation of DNA repair and the control of protein translation will highlight important aspects of cell biology. In addition, understanding the manner in which antiviral responses have been dismantled in tumor cells will identify pathways and approaches that can be exploited in the fight against cancer.
